Cutaneous lupus-like syndrome

Terbinafine has been associated with a cutaneous lupus-like syndrome [4 ]. 

Although patients treated with etanercept commonly develop new antinuclear antibodies or anti-double-stranded DNA antibodies, there were no reports of cutaneous or systemic lupus erythematosus in early clinical trials. However, since then, at least eight cases have been reported, including five patients with a lupus-like syndrome, two with acute discoid lupus, and one with subacute cutaneous lupus erythematosus (26-29). All were women and they developed their first symptoms 6 weeks to 14 months after the first injection of etanercept. Antinuclear and/or anti-DNA antibodies were positive in most of them. Etanercept was withdrawn in all patients with features of systemic lupus erythematosus, and the symptoms resolved within 2-8 weeks. The skin lesions also improved with local glucocorticoids, despite continued etanercept treatment in two patients with discoid lupus or subacute cutaneous lupus erythematosus. This suggests that etanercept-induced autoantibodies are sometimes associated with clinical autoimmune disease. 

Sandler, B. and Aronson, P. 1993. Yohimbine-induced cutaneous drug eruption, progressive renal failure, and lupus-like syndrome. Urology 41, 343-345. 

Immunologic Rowell s syndrome is the association of a lupus-like sjmdrome (systemic, subacute cutaneous, or discoid) together with eijdhema multiforme (including toxic epidermal necrolysis) and evidence of antinuclear antibodies and other... 

---